Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [1] Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways
    Huang, Linjuan
    Zhao, Ling
    Zhang, Jing
    He, Fang
    Wang, Hao
    Liu, Qing
    Shi, Deyao
    Ni, Na
    Wagstaff, William
    Chen, Connie
    Reid, Russell R.
    Haydon, Rex C.
    Luu, Hue H.
    Shen, Le
    He, Tong-Chuan
    Tang, Liangdan
    AGING-US, 2021, 13 (13): : 17407 - 17427
  • [2] Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer
    Wei, Wei
    Liu, Hongfang
    Yuan, Jia
    Yao, Yang
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 (01) : 165 - 173
  • [3] Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy
    Yu, Ge
    Nanding, Abiyasi
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2024, : 3097 - 3116
  • [4] Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells
    Horvath, Viktor
    Blanarova, Olga
    Svihalkova-Sindlerova, Lenka
    Soucek, Karel
    Hofmanova, Jirina
    Sova, Petr
    Kroutil, Ales
    Fedorocko, Peter
    Kozubik, Alois
    GYNECOLOGIC ONCOLOGY, 2006, 102 (01) : 32 - 40
  • [5] Niclosamide's potential direct targets in ovarian cancer
    Sekulovski, Nikola
    MacLean, James A., II
    Bheemireddy, Sambasiva R.
    Yu, Zhifeng
    Okuda, Hiroshi
    Pru, Cindy
    Plunkett, Kyle N.
    Matzuk, Martin
    Hayashi, Kanako
    BIOLOGY OF REPRODUCTION, 2021, 105 (02) : 403 - 412
  • [6] Niclosamide Analogs for Treatment of Ovarian Cancer
    Haygood, Christen L. Walters
    Arend, Rebecca C.
    Gangrade, Abhishek
    Chettiar, Somsundaram
    Regan, Nicholas
    Hassmann, Christopher J., II
    Li, Pui-Kai
    Hidalgo, Bertha
    Straughn, John Michael, Jr.
    Buchsbaum, Donald J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (08) : 1377 - 1385
  • [7] Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells
    Bao, Lingjie
    Jaramillo, Melba C.
    Zhang, Zhenbo
    Zheng, Yunxi
    Yao, Ming
    Zhang, Donna D.
    Yi, Xiaofang
    MOLECULAR MEDICINE REPORTS, 2015, 11 (01) : 91 - 98
  • [8] A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities
    Deng, Youlin
    Wang, Zhongliang
    Zhang, Fugui
    Qiao, Min
    Yan, Zhengjian
    Wei, Qiang
    Wang, Jing
    Liu, Hao
    Fan, Jiaming
    Zou, Yulong
    Liao, Junyi
    Hu, Xue
    Chen, Liqun
    Yu, Xinyi
    Haydon, Rex C.
    Luu, Hue H.
    Qi, Hongbo
    He, Tong-Chuan
    Zhang, Junhui
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 39 (03) : 871 - 888
  • [9] MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy
    Yu, J-L
    Gao, X.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (04) : 1688 - 1696
  • [10] Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
    Arend, Rebecca C.
    Londono-Joshi, Angelina I.
    Samant, Rajeev S.
    Li, Yonghe
    Conner, Michael
    Hidalgo, Bertha
    Alvarez, Ronald D.
    Landen, Charles N.
    Straughn, J. Michael
    Buchsbaum, Donald J.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (01) : 112 - 120
12345